Three Terminals Pulling Curve Pharmaceutical Terminals Will Have a New Round of Change

Business Club January 6 News 2011, is the starting point of the "Twelfth Five-Year Plan" and the continuation and landing of a series of changes in the pharmaceutical market last year. For this reason, the SFDA Institute of Southern Medicine Economics believes that with the "Twelve Five Years" With regard to the introduction of such policies as biopharmaceuticals, accelerating the reform of the medical service industry, and restructuring the pharmaceutical industry, a new round of major changes will take place in the medical terminal industry, and the pharmaceutical industry will benefit from this.

High-end hospitals: domestic and foreign investment on the same stage

The high-end hospital market is the major market for medical consumption in China and accounts for about 60% of total pharmaceutical sales. In recent years, due to the implementation of the universal health insurance policy in cities, outpatient coordinating, and increasing the proportion of reimbursement policies, the number of hospitals in urban hospitals has increased, and the use of drugs in hospitals in China has maintained rapid growth. The growth rate in the first half of 2010 reached 30.4%, and the total hospital drug use in the country was 4520. Billion yuan, a year-on-year increase of around 22%.

At the same time, large hospitals are also the main market for high-end products that have been dominated by foreign-funded products. In the first half of 2010, among the top 20 companies in the sample hospitals, 14 were foreign-funded enterprises, with an average increase of 32.7%, a total share of 21.1%, and the top five companies’ share was 11.7%; in China, there were only 6 companies with an average increase of 33.1%. The total share is 7.39%, and the top five companies have a share of 6.59%. It can be found that although the total market share of leading enterprises is still at a disadvantage, the growth of its hospital market has been slightly higher than that of foreign-funded enterprises, and Southern Data also shows that the total market share of foreign and joint venture products in high-end hospitals has been in recent years. Gradually reduce, the share of domestic brands of generic drugs is increasing.

In the country's “Special Major New Drug Development Project”, “Special Major generic name pharmaceutical industrialization” and other sustained high investment in the promotion of pharmaceutical research and development and product quality improvement policy implementation, as well as the domestic brand enterprises to actively promote the technology and product innovation, promoted jointly In the future, the use of domestically produced products in the hospital market will be effectively enhanced. The competitive landscape of the hospital market will present the situation in which domestic brand generic drugs compete with foreign drugs on the same stage. The rising proportion of domestic brand drugs in the high-end hospital market will become an important factor in boosting domestic demand.

However, to achieve this rapid result, there are still four areas that companies need to work harder: First, product quality is in line with international standards, actively responding to the implementation of new pharmacopoeia, new GMP, DMF and other regulations, and shortening generics with generic drugs and brands. The quality gap between the two; the second is to expand the scale of the company to achieve product and structure optimization, and promote resource agglomeration; the third is to actively explore innovative new varieties, and actively develop new formulations, focusing on blockbuster-level patent expired drugs; Strengthen cooperation with scientific research institutions and enterprises (including foreign companies) in the fields of scientific research and development and product sales.

Third Terminal: Expansion Expected Implementation

The third terminal covers more than 80% of China's population. It mainly undertakes basic medical services for the grassroots people and is also expected by the country's new medical reform.

The biggest aspect of the third terminal is how the basic drug system is implemented. The state requires a three-year, phase-by-phase implementation of a basic drug system in grass-roots hospitals across the country. The zero-difference rate of drug implementation will significantly increase the level of funding for the new rural cooperative medical system. In addition, in order to improve the medical level and service level of primary-level medical institutions, the state has invested heavily in the construction of a number of primary-level medical institutions to improve their hardware measures. To date, China has established 554,000 rural drug supply outlets and community health service centers (stations) 2.6 Ten thousand township hospitals have 39,000 homes.

However, more than a year after the implementation of the new medical reform and basic medicine system, the increase in the consumption of medicines at the primary level medical institutions did not show a significant increase. In 2010, the estimated annual medical use scale was 129.7 billion yuan, an increase of approximately 27.9% over the same period of last year. The main reason is that there is no significant increase in the number of outpatients in medical institutions, and in most areas, the gap between the revenue and expenditure of the hospital and the shortage of some varieties are high. The enthusiasm of basic hospitals is not high.

Through a one-year pilot project, in December 2010, the State issued the “Guiding Opinions on the Basic Drug Purchase Mechanism of Government-run Medical Institutions (Draft for Soliciting Opinions)”. The idea was designed using “quantity-price-linked” and “double-envelope” methods. Later, they also issued the Opinions on Establishing and Perfecting the Compensation Mechanism for Primary Health Care Institutions, clarifying that the primary hospital's hardware is fully invested in the government, the general medical expenses are adjusted by the medical insurance, and the hospital's regular revenues and expenditures are insufficient by the government's budget. Arrange the compensation mechanism for (pre-dial and post settlement). The two documents were introduced to solve the problems in the aforementioned pilot projects. After more than a year of foundation, the grass-roots medical institutions have been able to undertake new medical reforms after a series of measures such as the transformation of hardware, personnel training, and income subsidies by the state. Although there is still uncertainty about local protection of medicines, local financial capacity, and lack of willingness in the ability to achieve medical insurance, the third terminal market after 2011 is more likely to grow.

However, it is worth noting that after the institutional guarantee and capital investment, there is a key issue that is the establishment and improvement of the referral system for primary medical institutions. At present, the large hospitals account for more than 55% of the attending population, while the primary medical institutions account for less than 6% of the total. Under the tendency and judgment of domestic residents on existing medical services, how can the basic medical institutions provide service capabilities and service levels? It is the next key point to win the trust of the people and issue a corresponding compulsory referral system to achieve a balanced distribution and full use of medical resources.

Retail Terminal: Decisive High Maori Products

The retail terminal market share accounts for about one-fourth of the total pharmaceutical consumption, and it is the only area that is currently fully market-oriented. Since 2003, China's retail terminal drug use has increased steadily. The sales volume in 2009 was 148.7 billion yuan, an increase of approximately 14.8% year-on-year, and approximately 179.3 billion yuan in 2010.

According to statistics from the Southern Institute of Statistics, as of the first half of 2010, the number of domestic retail pharmacies was 394,200, and the growth rate slowed down. From the point of view of domestic single-store sales, the average pharmacy store sales in China in 2009 were 390,000 yuan, while the average US sales of WALGRENS, with the highest single-store sales, reached 9.04 million. With the increase in the number of pharmacies and the low sales capacity of single stores, the pharmacy continued to chase high-margin products without changing the gross margin of domestic pharmacies' operating margin of at least 30%. The brand drugs terminal interception remains unchanged. serious.

In addition, the increase in zero-difference rate of the base medicine and the improvement of community service capabilities will have an increased impact on retail terminals. Older drug users and people with chronic drug use will gradually shift to the community, and the impact on designated drugstores will increase.

However, we cannot ignore that the development direction of pharmacies is diversification. With the investment of the state and pharmaceutical companies in residents' health education, the residents’ awareness of self-medication will inevitably drive the growth of the retail terminal market. In the future, home medical equipment, drug makeup, health care products, precious and rare medicinal materials, etc. will become profitable for pharmacies. The important source.

Chocolate Melting Machine

Chocolate Melting Machine,Chocolate Melting Maker,Commercial Chocolate Melting Machine,Commercial Chocolate Melting Maker

Guangzhou New Power Catering Equipment Manufacturing Co.,Ltd , https://www.gznewpower.com

Posted on